Immuno‐Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD‐L1 Testing May Not Be Enough

PURPOSE. The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transformed by the U.S. Food and Drug Administration approval of pembrolizumab. Tumor and adjacent tissue must stain positively for the programmed cell death ligand 1 (PD‐L1) prote...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Weinberg, Benjamin A., Xiu, Joanne, Hwang, Jimmy J., Shields, Anthony F., Salem, Mohamed E., Marshall, John L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2018
Aiheet:
Gastrointestinal Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6263127/
https://ncbi.nlm.nih.gov/pubmed/29703766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0034
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia